基本信息
李盈 女 上海有机化学研究所
电子邮件:Ying_Li2@hms.harvard.edu
通信地址:
邮政编码:

研究领域

化学生物学
细胞生物学
药物筛选

招生信息

   
招生专业
070303-有机化学
071009-细胞生物学
招生方向


专利与奖励

   
专利成果
( 1 ) 一类细胞程序性坏死抑制剂及其制备方法和用途, 发明专利, 2025, 第 2 作者, 专利号: ZL 2021 8 0063390.5

( 2 ) 一类基于有机砷的II型丙酮酸激酶抑制剂及其制备方法和用 途, 发明专利, 2025, 第 2 作者, 专利号: ZL 2020 1 0653333.X

( 3 ) プログラム細胞壊死阻害剤およびその調製方法 、ならびに使用, 发明专利, 2025, 第 2 作者, 专利号: 特許第7642799号

( 4 ) 一类细胞程序性坏死抑制剂及其制备方法和用途, 发明专利, 2024, 第 2 作者, 专利号: ZL 2019 1 0425587.3

( 5 ) 一类基于有机胂的CDK抑制剂及其制备方法和用途, 发明专利, 2024, 第 2 作者, 专利号: ZL 2019 1 0925781.8

( 6 ) 一类基于有机砷的II型丙酮酸激酶抑制剂及其制备方法和用途, 发明专利, 2021, 第 2 作者, 专利号: CN113801163A

( 7 ) Programmed cell necrosis inhibitor, preparation method therefor, and use thereof, 发明专利, 2021, 第 2 作者, 专利号: US20230331707A1

( 8 ) 一类基于有机胂的CDK抑制剂及其制备方法和用途, 发明专利, 2021, 第 2 作者, 专利号: CN112574255A

( 9 ) 一类细胞坏死抑制剂及其制备方法和用途, 发明专利, 2021, 第 9 作者, 专利号: CN112543755A

( 10 ) 一类细胞程序性坏死抑制剂及其制备方法和用途, 发明专利, 2020, 第 2 作者, 专利号: CN111978311A

出版信息

   
发表论文
(1) RIPK1 Drives JAK1‐STAT3 Signaling to Promote CXCL1‐Mediated Neutrophil Recruitment in Sepsis‐Induced Lung Injury, Advanced Science, 2025, 
(2) Discovery of SARS-CoV-2 PLpro inhibitors and RIPK1 inhibitors with synergistic antiviral efficacy in a mouse COVID-19 model, cta Pharmaceutica Sinica B, 2025, 
(3) Structure-based development of potent and selective type-II kinase inhibitors of RIPK1, Acta Pharmaceutica Sinica B, 2024, 
(4) Structural mechanism for specific binding of chemical compounds to amyloid fibrils, NATURE CHEMICAL BIOLOGY, 2023, 第 9 作者
(5) Selective Covalent Targeting of Pyruvate Kinase M2 Using Arsenous Warheads, JOURNAL OF MEDICINAL CHEMISTRY, 2023, 第 16 作者  通讯作者
(6) Small molecule activators of TAK1 promotes its activity- dependent ubiquitination and TRAIL- mediated tumor cell death, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2023, 第 19 作者  通讯作者
(7) SOX17 and PAX8 constitute an actionable lineage-survival transcriptional complex in ovarian cancer, ONCOGENE, 2022, 第 15 作者
(8) PP6 negatively modulates LUBAC-mediated M1-ubiquitination of RIPK1 and c-FLIPL to promote TNFα-mediated cell death, CELL DEATH AND DISEASE, 2022, 第 11 作者  通讯作者
(9) Discovery of Potent OTUB1/USP8 Dual Inhibitors Targeting Proteostasis in Non-Small-Cell Lung Cancer, JOURNAL OF MEDICINAL CHEMISTRY, 2022, 第 13 作者
(10) Dual Inhibition of CDK12/CDK13 Targets Both Tumor and Immune Cells in Ovarian Cancer, CANCER RESEARCH, 2022, 第 15 作者
(11) HOIP modulates the stability of GPx4 by linear ubiquitination, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2022, 第 9 作者  通讯作者
(12) RIPK1 regulates starvation resistance by modulating aspartate catabolism, NATURE COMMUNICATIONS, 2021, 第 7 作者
(13) Discovery of a cooperative mode of inhibiting RIPK1 kinase, CELL DISCOVERY, 2021, 第 11 作者
(14) Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2, CELL CHEMICAL BIOLOGY, 2021, 第 16 作者  通讯作者
(15) NEK1-mediated retromer trafficking promotes blood-brain barrier integrity by regulating glucose metabolism and RIPK1 activation, NATURE COMMUNICATIONS, 2021, 第 12 作者
(16) SARS-CoV-2 promotes RIPK1 activation to facilitate viral propagation, SARS-CoV-2 promotes RIPK1 activation to facilitate viral propagation, CELL RESEARCH, 2021, 第 2 作者
(17) Hsp27 chaperones FUS phase separation under the modulation of stress-induced phosphorylation, NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2020, 第 12 作者
(18) TAM Kinases Promote Necroptosis by Regulating Oligomerization of MLKL, MOLECULAR CELL, 2019, 第 7 作者
(19) A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader, CELL CHEMICAL BIOLOGY, 2018, 第 14 作者
(20) TBK1 suppresses RIPK1-driven apoptosis and inflammation during development and in aging, CELL, 2018, 第 14 作者
(21) Death-domain dimerization-mediated activation of RIPK1 controls necroptosis and RIPK1-dependent apoptosis, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2018, 第 11 作者  通讯作者
(22) PELI1 functions as a dual modulator of necroptosis and apoptosis by regulating ubiquitination of RIPK1 and mRNA levels of c-FLIP, PROCEEDINGSOFTHENATIONALACADEMYOFSCIENCESOFTHEUNITEDSTATESOFAMERICA, 2017, 第 8 作者
(23) Systematic Metrics Depicting Cell Death Kinetics, CELL CHEMICAL BIOLOGY, 2017, 第 1 作者
(24) Small molecule probes for cellular death machines, CURRENT OPINION IN CHEMICAL BIOLOGY, 2017, 第 1 作者
(25) RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS, SCIENCE, 2016, 第 6 作者
(26) Modification of BECN1 by ISG15 plays a crucial role in autophagy regulation by type I IFN/interferon, AUTOPHAGY, 2015, 第 8 作者
(27) Control of Life-or-Death Decisions by RIP1 Kinase, ANNUAL REVIEW OF PHYSIOLOGY, VOL 76, 2014, 第 2 作者
(28) Necrostatin-1: Its Discovery and Application in Cell Death Research, Necrotic Cell Death, 2014, 第 1 作者
(29) A novel necroptosis inhibitor-necrostatin-21 and its SAR study, BIOORG. MED. CHEM. LETT., 2013, 第 2 作者
(30) A novel role for RIP1 kinase in mediating TNF α production, CELL DEATH & DISEASE, 2012, 
(31) Beclin1 Controls the Levels of p53 by Regulating the Deubiquitination Activity of USP10 and USP13, CELL, 2011, 第 5 作者
(32) Beclin1 Controls the Levels of p53 by Regulating the Deubiquitination Activity of USP10 and USP13, CELL, 2011, 第 5 作者
(33) Negative regulation of interferon-gamma/STAT1 signaling through cell adhesion and cell density-dependent STAT1 dephosphorylation, CELLULAR SIGNALLING, 2011, 第 6 作者
(34) Cyclodepsipeptide toxin promotes the degradation of Hsp90 client proteins through chaperone-mediated autophagy, JOURNAL OF CELL BIOLOGY, 2009, 第 4 作者
(35) 17-acetoxyjolkinolide b irreversibly inhibits i kappa b kinase and induces apoptosis of tumor cells, MOLECULAR CANCER THERAPEUTICS, 2008, 第 2 作者
(36) 三类分子化合物调控肿瘤细胞生长与死亡的功能及机理研究, 2008, 第 1 作者

科研活动

   
科研项目
( 1 ) 东方英才拔尖项目, 负责人, 地方任务, 2025-01--2027-12
( 2 ) RIPK1激酶介导炎症反应的分子机制及干预手段研究, 负责人, 国家任务, 2022-01--2025-12
( 3 ) 细胞程序性坏死关键蛋白RIPK1/RIPK3泛素化调控机制的研究, 负责人, 国家任务, 2019-01--2021-12
( 4 ) Helenalin调控程序性坏死和抗炎作用机理探索, 负责人, 其他, 2015-01--2017-12
( 5 ) 细胞程序性坏死抑制剂SNR001-01治疗肝损伤的临床前研究, 参与, 国家任务, 2014-01--2016-12